U.S. refiners with strong buy ratings are expected to benefit significantly from the global fuel crisis, driven by record-high diesel prices and elevated gasoline costs. Capacity constraints due to geopolitical tensions and a tight California market are boosting refining margins, with the diesel-crude crack spread surpassing $100 per barrel. Even if oil prices decline, refining profits may remain strong. Analyst Steven Cress highlights three refining stocks well-positioned to capitalize on this supply shock, offering momentum and profitable growth potential.
The global fuel crisis and its impact on refiners provide context for energy sector activity on Pluang. For readers following energy stocks, here is Pluang's market snapshot as of Sep 17, 2026 23:42 WIB: out of 30 priced US energy-sector stocks, 20 rose and 10 fell. Notable movers include XOM at USD 162.21 with a 1-day change of -0.69% and Pluang order activity of 71% Sell / 29% Buy; INDO at USD 2.92, up 0.69%, with 25% Sell / 75% Buy; and TTE at USD 91.43, up 0.65%, with 98% Sell / 2% Buy.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
